LM-338 / Sino Biopharm, LaNova Medicines Limited - LARVOL DELTA

Preclinical evaluation of LM-338: An innovative anti-STn antibody drug conjugate for solid tumors (AACR 2026) - "LM-338, an anti-STn ADC, demonstrated potent anti-tumor activityacross several solid tumor models with favorable preclinical tolerability. These findings support further clinical development of LM-338 for patients with STn-expressingmalignancies.Keywords: STn, antibody-drug conjugate, LM-338, solid tuomrs, ovarian cancer, colorectal cancer, lung cancerDisclosure: The study was funded by LaNova Medicines Limited, China."

ADC • Preclinical • Colorectal Cancer • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor